PDF icon PDF herunterladen
Open Access
CC BY 4.0 · Indian J Med Paediatr Oncol
DOI: 10.1055/s-0045-1811936
Original Article

Olanzapine versus Aprepitant for Prophylaxis of Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy: A Prospective Randomized Study

Lakshmi D. Gedela
1   Department of Medical Oncology, Konaseema Institute of Medical Sciences, Amalapuram, Andhra Pradesh, India
,
Rachana Chennamaneni 
2   Department of Medical Oncology, Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India
,
Konatam Meher Lakshmi
2   Department of Medical Oncology, Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India
,
Stalin Chowdary Bala
3   Department of Medical Oncology, Mahatma Gandhi Cancer Institute, Visakhapatnam, Andhra Pradesh, India
,
Sadashivudu Gundeti 
2   Department of Medical Oncology, Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India
› Institutsangaben
› Weitere Informationen
Auch verfügbar aufeRef
  Lizenzen und Reprints
Preview

Abstract

Introduction

Chemotherapy-induced nausea and vomiting (CINV) negatively affects health-related quality of life and performance status in patients undergoing chemotherapy. Aprepitant, palonosetron, and steroids (APD) notably enhance the rates of complete response (CR) in patients receiving highly emetogenic chemotherapy (HEC). This study compares the efficacy, cost, and quality of life between APD and olanzapine, palonosetron, and dexamethasone (OPD).

Objectives

The main aim of the study was to evaluate the control of CINV by measuring CR and total control (TC). The secondary aim was to examine the impact of CINV on patients' quality of life.

Materials and Methods

This is a prospective randomized study of patients newly diagnosed with malignancy, aged > 18 years. This analysis was done over a period of 1 year in patients receiving HEC. All patients eligible for the study are randomized to APD versus OPD regimen. Stratification was done according to the chemotherapy regimen used. Quality of life, the secondary objective, was assessed by using the Functional Living Index-Emesis.

Results

Overall, 120 patients were randomized during the study period to both the arms at 1:1 ratio. Baseline characteristics were equally matched between both the arms. Both the arms showed effective prevention of vomiting in nearly 80% of the study population. Emesis was reported in 19% of APD and 20% in the OPD arm (p = 0.75). Grade 3/4 vomiting was not seen in any patient in the olanzapine group. The CR rates in all patients are 75 and 77% with APD and OPD arms, respectively (p = 0.83). Overall, the TC of CINV is similar among the two groups, 57 and 60% in APD and OPD, respectively (p = 0.85). Delayed nausea was significantly lower in the OPD arm compared with APD (17% vs. 38%, respectively, p = 0.025). In patients receiving anthracycline plus cyclophosphamide chemotherapy, OPD outperformed APD in delayed nausea and delayed TC (p = 0.002 and 0.015, respectively). Both drugs were effective in maintaining a good quality of life and no significant difference was observed among both the groups. The most common toxicity observed in both the arms was anorexia.

Conclusion

Both regimens had similar efficacy in preventing CINV, with no significant differences in CR and TC rates. Olanzapine was more effective for delayed nausea than aprepitant, suggesting it is a cost-efficient alternative for managing CINV in HEC patients.

Keywords

aprepitant - olanzapine - highly emetogenic chemotherapy - nausea and vomiting

Note

This work was presented virtually at the MASCC/ISOO 2021 Conference on June 24, 2021.


Authors' Contributions

We assure that the manuscript has been read and approved by all the authors, the requirements for authorship have been met, and each author believes that the manuscript represents honest work.


Patients' Consent

Informed consent has been taken from all the patients randomized in this study.




Publikationsverlauf

Artikel online veröffentlicht:
25. September 2025

© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Sharma R, Tobin P, Clarke SJ. Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea. Lancet Oncol 2005; 6 (02) 93-102
    CrossrefPubMedSuche in Google Scholar
  • 2 Hickok JT, Roscoe JA, Morrow GR. et al. Use of 5-HT3 receptor antagonists to prevent nausea and emesis caused by chemotherapy for patients with breast carcinoma in community practice settings. Cancer 1999; 86 (01) 64-71
    CrossrefPubMedSuche in Google Scholar
  • 3 Holdsworth MT, Raisch DW, Frost J. Acute and delayed nausea and emesis control in pediatric oncology patients. Cancer 2006; 106 (04) 931-940
    CrossrefPubMedSuche in Google Scholar
  • 4 Hesketh PJ, Grunberg SM, Gralla RJ. et al; Aprepitant Protocol 052 Study Group. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin–the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003; 21 (22) 4112-4119
    CrossrefPubMedSuche in Google Scholar
  • 5 Poli-Bigelli S, Rodrigues-Pereira J, Carides AD. et al; Aprepitant Protocol 054 Study Group. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003; 97 (12) 3090-3098
    CrossrefPubMedSuche in Google Scholar
  • 6 Schmoll HJ, Aapro MS, Poli-Bigelli S. et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 2006; 17 (06) 1000-1006
    CrossrefPubMedSuche in Google Scholar
  • 7 Navari RM. Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV). Drug Des Devel Ther 2014; 9 (01) 155-161
    CrossrefPubMedSuche in Google Scholar
  • 8 Ng TL, Hutton B, Clemons M. Chemotherapy-induced nausea and vomiting: time for more emphasis on nausea?. Oncologist 2015; 20 (06) 576-583
    CrossrefPubMedSuche in Google Scholar
  • 9 Navari RM, Einhorn LH, Passik SD. et al. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Support Care Cancer 2005; 13 (07) 529-534
    PubMedSuche in Google Scholar
  • 10 Passik SD, Navari RM, Jung SH. et al. A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study. Cancer Invest 2004; 22 (03) 383-388
    CrossrefPubMedSuche in Google Scholar
  • 11 Passik SD, Lundberg J, Kirsh KL. et al. A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manage 2002; 23 (06) 526-532
    CrossrefPubMedSuche in Google Scholar
  • 12 National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Antiemesis [v.2.2024]. 2024
    Suche in Google Scholar
  • 13 GraphPad Prism version 10.0.0 for Windows, GraphPad Software, Boston, Massachusetts, USA. Accessed September 2, 2025 at: www.graphpad.com
  • 14 Kuchuk I, Bouganim N, Beusterien K. et al. Preference weights for chemotherapy side effects from the perspective of women with breast cancer. Breast Cancer Res Treat 2013; 142 (01) 101-107
    CrossrefPubMedSuche in Google Scholar
  • 15 Navari RM, Einhorn LH, Loehrer Sr PJ. et al. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study. Support Care Cancer 2007; 15 (11) 1285
    PubMedSuche in Google Scholar
  • 16 Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 2011; 9 (05) 188-195
    CrossrefPubMedSuche in Google Scholar
  • 17 Tan L, Liu J, Liu X. et al. Clinical research of olanzapine for prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res 2009; 28 (01) 131
    CrossrefPubMedSuche in Google Scholar
  • 18 Babu G, Saldanha SC, Kuntegowdanahalli Chinnagiriyappa L. et al. The efficacy, safety, and cost benefit of olanzapine versus aprepitant in highly emetogenic chemotherapy: a pilot study from South India. Chemother Res Pract 2016; 2016: 3439707
    PubMedSuche in Google Scholar
  • 19 Zhang Z, Zhang Y, Chen G. et al. Olanzapine-based triple regimens versus neurokinin-1 receptor antagonist-based triple regimens in preventing chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy: a network meta-analysis. Oncologist 2018; 23 (05) 603-616
    CrossrefPubMedSuche in Google Scholar
  • 20 Sarma I, Buragohain S, Lahon J. et al. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis. Cureus 2025; 17 (04) e83118
    PubMedSuche in Google Scholar
  • 21 Shivaprakash G, Udupa KS, Sarayu V. et al. Olanzapine versus aprepitant for the prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving doxorubicin-cyclophosphamide regimen: a prospective, nonrandomized, open-label study. Indian J Pharmacol 2017; 49 (06) 451-457
    CrossrefPubMedSuche in Google Scholar
  • 22 Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 2006; 24 (27) 4472-4478
    CrossrefPubMedSuche in Google Scholar
  • 23 Mohammed O, Thota NK. Efficacy, safety, and cost-effectiveness of reduced-dose olanzapine versus aprepitant as a part of triple-antiemetic therapy in the prevention of chemotherapy-induced nausea and vomiting. J Clin Oncol 2022; 40: e24078-e24078
    CrossrefSuche in Google Scholar
  • 24 Badarudin NS, Mohamed Shah N, Mohd Tahir NA. et al. Health-related quality of life and economic analysis of olanzapine versus aprepitant in preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Malaysia. Value Health Reg Issues 2024; 44: 101028
    CrossrefPubMedSuche in Google Scholar